Search

Your search keyword '"Taskinen MR"' showing total 616 results

Search Constraints

Start Over You searched for: Author "Taskinen MR" Remove constraint Author: "Taskinen MR"
616 results on '"Taskinen MR"'

Search Results

1. 2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk (vol 290, pg 140, 2019)

2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

3. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

4. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

5. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

6. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men

7. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

8. Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study

9. Characterizing human adipose tissue lipids by long echo time 1H-MRS in vivo at 1.5 Tesla: validation by gas chromatography

10. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

11. ESC/EAS Guidelines for the management of dyslipidaemias

12. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

13. ESC/EAS Guidelines for the management of dyslipidaemias (vol 32, pg 1769, 2011)

14. ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary

15. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

16. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

17. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort

20. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

23. What does postprandial hyperglycaemia mean?

26. A Genome-Wide Screen for Interactions Reveals a New Locus on 4p15 Modifying the Effect of Waist-to-Hip Ratio on Total Cholesterol

27. Use of Genome-Wide Expression Data to Mine the 'Gray Zone' of GWA Studies Leads to Novel Candidate Obesity Genes

28. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

30. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

33. Verbesserung von Betazellfunktion und glykämischer Kontrolle nach einem Jahr Therapie mit Exenatide bei Metformin-behandelten Patienten mit Typ-2-Diabetes

34. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23.

37. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.

38. Reviewing statin therapy in diabetes--towards the best practise.

39. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.

40. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

41. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

42. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

44. Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men

45. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [corrected] [published erratum appears in LANCET 2006 Oct 21-27;368(9545):1420].

46. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

47. Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia

48. Multi-omics characterization of lymphedema-induced adipose tissue resulting from breast cancer-related surgery.

49. Biosynthesis and Metabolism of ApoB-Containing Lipoproteins.

50. Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation.

Catalog

Books, media, physical & digital resources